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The secondary fungal metabolite gliotoxin targets proteolytic
activities of the proteasome
Mathias Kroll1, Fernando Arenzana-Seisdedos1, Françoise Bachelerie1,
Dominique Thomas1, Bertrand Friguet2 and Mariangela Conconi2
Background: The fungal epipolythiodioxopiperazine metabolite gliotoxin has a
variety of toxic effects such as suppression of antigen processing, induction of
macrophagocytic apoptosis and inhibition of transcription factor NF-κB
activation. How gliotoxin acts remains poorly understood except that the
molecule’s characteristic disulfide bridge is important for immunomodulation. As
this fungal metabolite stabilizes the NF-κB inhibitor IκBα in the cytoplasm, we
decided to investigate its molecular mechanism of action.
Results: We show that gliotoxin is an efficient, noncompetitive inhibitor of the
chymotrypsin-like activity of the 20S proteasome in vitro. Proteasome inhibition
can be reversed by dithiothreitol, which reduces gliotoxin to the dithiol
compound. In intact cells, gliotoxin inhibits NF-κB induction through inhibition of
proteasome-mediated degradation of IκBα.
Conclusions: Gliotoxin targets catalytic activities of the proteasome
efficiently. Inhibition by gliotoxin may be countered by reducing agents, which
are able to inactivate the disulfide bridge responsible for the inhibitory
capacity of gliotoxin.
Introduction
Invasive fungal infections are among the most serious
problems in immunocompromised patients, causing ele-
vated mortality rates [1–2]. The precise molecular mecha-
nisms of many fungal pathogeneses are unclear, but one
possible agent is the secondary fungal metabolite gliotoxin
that contributes to the immunosupressive and other toxic
effects of infections by opportunistic pathogens including
Aspergillus fumigatus and Candida albicans [3–5]. Gliotoxin
and related compounds can be life-threatening for
immunocompromised individuals such as AIDS patients
suffering from disseminated aspergillosis. Gliotoxin has a
variety of antimicrobial effects [3] and induces apoptosis in
different cell types such as macrophages, thymocytes,
spleen cells and cells of the mesenteric lymph nodes [2–6].
Gliotoxin and related molecules are members of the
fungal epipolythiodioxopiperazine toxins, a compound
class characterized by a heterobicyclic core containing a
polysulfide bridge (2–4 atoms of sulfur) [3–7]. The sulfide
bridge plays a crucial role in the toxic effect, because its
chemical elimination abolishes inhibition of virus prolifer-
ation and bacterial or eukaryotic cell proliferation [8]. It is
known that low molecular weight thiols may protect cells
against the toxic effects of gliotoxin. Several studies sug-
gested a potential interaction involving the formation of
mixed disulfide bonds between the toxin’s sulfide groups
and the disulfide or thiol groups of cellular proteins to
explain the mechanism of gliotoxin action [7–10].
Pahl et al. [11] reported that gliotoxin is a potent inhibitor
of transcription factor nuclear factor κB (NF-κB) activation
in T and B cells induced in response to a variety of stimuli.
Heterodimers of p50/p65 are the most abundant members
of the Rel/NF-κB family of transcription factors that con-
trols the expression of a wide variety of genes implicated in
immune responses, inflammation and cellular proliferation.
Dysregulation of NF-κB is associated with cellular trans-
formation and the maintenance of a high anti-apoptotic
threshold in transformed cells. NF-κB activity is regulated
by its sequestration in the cytoplasm by the inhibitor of κB
α (IκBα), which is susceptible to proteasome-mediated
degradation [12,13]. Following cell activation, IκBα is
phosphorylated on serine residues 32 and 36 [14–18], and
ubiquitinated on lysine residues 21, 22, and the accessory
residues 38 and 47 [19–21]. Ubiquitination of IκBα is
achieved by an ubiquitin-conjugating activity possibly con-
sisting of several different enzymes [22] working with an
E3 enzyme complex of the SCF-type (for Skp1-Cullin-F-
box-containing protein complex [23]), the receptor compo-
nent of which is the F-box protein family member
β-transducin-repeat-containing protein (βTrCP) [24–27].
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Through a mechanism still under investigation, IκBα is
then targeted for degradation by the proteasome [19–21].
The multicatalytic proteolytic complex generally referred
to as proteasome occurs in several forms in eukaryotic cells
[28] — the 26S proteasome or the 20S proteasome that
may associate or not with modulatory subunits. Protea-
somes are pivotal in the control of the cell cycle, cell divi-
sion and differentiation, development, DNA repair,
regulation of immune and inflammatory responses, apopto-
sis, antigen presentation, modulation of the expression of
cell surface receptors, and transcription of genes requiring
participation of certain transcription factors such as NF-κB
and activating protein 1 (AP-1) [28]. 
The 20S proteasome is a high molecular mass (700 kDa)
protease present in the cytoplasm and nucleus of eukary-
otic cells and represents up to 1% of total cellular protein
[29–31]. It is composed of four stacked rings, each of
which carries seven subunits of 21–35 kDa, the inner rings
containing the β subunits and the outer rings the α sub-
units [32]. The rings of the eukaryotic proteasome are
composed of up to 14 different subunits that have at least
three different catalytic activities, the trypsin-like, chymo-
trypsin-like and peptidylglutamyl-peptide hydrolase activ-
ities, localizing to three active sites [33,34]. The cleavage
of peptide bonds at the carboxyl end of branched-chain
amino acids and between short-chain neutral amino acids
has also been described [35].
Because of the central role of proteasomes in the activa-
tion of NF-κB, we decided to study the possibility that
gliotoxin has an inhibitory effect on the proteolytic activi-
ties of proteasomes. We show that gliotoxin inhibits the
degradation of the succinylated fluorogenic peptide
leucine–leucine–valine–tyrosine–amidomethylcoumarin
(Suc–LLVY–amc), which is cleaved by the chymotrypsin-
like activity of the proteasome in a noncompetitive
manner, but does not affect the proteases trypsin, chy-
motrypsin and calpain. We also present evidence that
gliotoxin administration precludes IκBα degradation in
vitro and in cell culture and is therefore responsible for
suppression of NF-κB activation.
Results and discussion
Gliotoxin inhibits NF-κB activation by stabilizing IκBα
Administration of low doses of gliotoxin is sufficient to
prevent tumor necrosis factor (TNF)-induced NF-κB
activation in HeLa cells or peripheral blood mononuclear
cells. Gliotoxin (1 µM) was added to the culture medium
of HeLa cells. Following stimulation by TNF, the cyto-
plasm and the nucleoplasm were fractionated, and nuclear
extracts were analysed using an electrophoretic mobility
shift assay (EMSA; Figure 1a). Results show that a
30 minute exposure to gliotoxin prevents NF-κB binding
beyond its baseline level constitutively present in HeLa
cells, and after 2 hours of preincubation, gliotoxin is even
able to down-regulate the constitutive level of NF-κB
binding (Figure 1a, compare lanes 1, 4 and 5), presumably
by inhibiting at least part of the basal turnover of IκBα.
When cells were exposed to gliotoxin, TNF stimulation
was no longer able to provoke significant NF-κB binding
(compare lanes 2 and 6). Accordingly, a stabilization of
IκBα in cytoplasmic extracts of gliotoxin-treated cells is
observed following TNF stimulation (Figure 1b). To
ascertain that down-regulation of IκBα proteolysis is
really caused by proteasome inhibition and not by inter-
ference with signal transduction, we tested whether
gliotoxin could prevent the accumulation of ubiquitinated
forms of IκBα or prevent its binding to the receptor com-
ponent of the E3 SCF-type ubiquitin ligase, βTrCP
[24–27]. For this purpose, HeLa cells, treated or not with
TNF in the presence and absence of gliotoxin and/or the
proteasome inhibitor Z–LLL–H (also called MG132), were
lysed in a buffer containing the alkylating agent iodoac-
etamide (10 mM) that blocks ubiquitin carboxy-terminal
hydrolases and isopeptidases. In immunoblots, phospho-
rylated and ubiquitinated IκBα could be detected when
cells had been treated with 1 µM of gliotoxin and/or
20 µM of Z–LLL–H, and stimulated with TNF for
20 minutes (Figure 1c). In addition, we carried out an
in vitro test of the ability of gliotoxin to interfere with
ubiquitin-transfer reactions from yeast E1 to recombinant
E2 CDC34. As can be seen from Figure 1d, 10 µM
gliotoxin does not inhibit ubiquitin transfer in an E1/E2 in
vitro system containing yeast E1, CDC34 and radiola-
beled glutathione-S-transferase (GST)–ubiquitin. More-
over, phospho-IκBα was still able to bind to, and
coprecipitate with, βTrCP and βTrCP∆F, an F-box dele-
tion mutant of βTrCP [27], in the presence of 1 µM
gliotoxin (Figure 1e). As the ubiquitinated forms of IκBα
observed in the presence of gliotoxin depend on the pre-
ceding phosphorylation of serine residues 32 and 36, we
conclude that gliotoxin does not significantly interfere
with IκBα phosphorylation, which is in agreement with
the findings described previously [11]. Taken together,
these results indicate that gliotoxin does not significantly
interfere with signal-induced modifications of IκBα, but
merely with its proteasome-mediated degradation, as sug-
gested by our in vitro experiments. Previously, we showed
that the amino and carboxyl termini of IκBα, with the car-
boxyl terminus being the noninducible part of the signal
responsible for determining susceptibility to degradation
by the catalytic core of the proteasome [36]. The suppres-
sion of NF-κB activation may therefore be caused by the
inhibition of proteasome-resident catalytic activities by
gliotoxin. To further confirm this hypothesis, we exam-
ined four other known proteasome substrates, p53 [37],
β-catenin [38], dihydrofolate reductase (DHFR) [39] and
ornithine decarboxylase (ODC) [40], whose regulatory
pathways leading to proteasome-mediated degradation are
different from that of IκBα. ODC is a ubiquitin-indepen-
dent proteasome substrate. 
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Exposure of interleukin-2-activated peripheral blood
mononuclear cells to 10 µM gliotoxin stabilized these sub-
strates over a period of 4 hours, albeit to a lesser extent
than 10 µM Z–LLL–H (Figure 2a, compare lanes 1, 2 and
4 for p53 and β-catenin). The effect of gliotoxin could be
reversed by addition of the reducing agent dithiothreitol
(DTT; 1 µM) to the culture medium (Figure 2a, compare
lanes 1, 2 and 3). Equally, gliotoxin administration elicited
the accumulation of DHFR (Figure 2b) by a factor of 1.3,
as measured by an enzymatic assay, and of ODC
(Figure 2c) by a factor of 6.6, as measured by semiquanti-
tative image analysis using a scanning confocal microscope
(in control reactions, there was no measurable fluores-
cence light emission from gliotoxin-treated or gliotoxin-
untreated cells when the ODC antibody was replaced by a
nonspecific control antibody).
Gliotoxin affects primarily the chymotrypsin-like peptidase
activity of the 20S proteasome
We examined the effect of two different gliotoxin con-
centrations (40 µM and 100 µM) on the degradation of
three different fluorogenic peptides: Suc–LLVY–amc,
LSTR–amc, and LLE–na, which are targets of the 
different proteolytic activities of proteasomes (see the
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Figure 1
Gliotoxin inhibits NF-κB activation in intact
cells by stabilizing phosphorylated and
ubiquitinated IκBα. (a) Down-regulation of
NF-κB activation by gliotoxin. HeLa cells were
exposed to 1 µM gliotoxin where indicated,
stimulated with TNF or left untreated during
the indicated time periods, lysed, fractionated
and subjected to an electrophoretic mobility
shift assay. Nuclear extracts (4 µg) were
probed with a 32P-labeled oligonucleotide
containing six consecutive binding sites for
NF-κB (κB elements) taken from the long
terminal repeat of HIV-1. Lanes 1–3, no
gliotoxin; lanes 4–6, 1 µM gliotoxin. Lane 3, in
the absence of gliotoxin and in the presence
of the unlabeled, added in excess over the
radioactive, probe (indicated by an asterisk).
ns, nonspecific signal. (b) Stabilization of
IκBα by gliotoxin. HeLa cells were exposed to
1 µM gliotoxin (bottom) or not (top) and lysed
after TNF stimulation. Cytoplasmic extracts
were fractionated using sodium dodecyl
sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) and blotted onto nitrocellulose.
IκBα was detected by monoclonal antibody
10B. (c) Insignificant interference of gliotoxin
with IκBα signal-induced modification.
Detection of ubiquitinated (top panel) and
phosphorylated (bottom panel) forms of IκBα
in the presence of gliotoxin. Exposures were
taken from the same gel. HEK293 cells were
left untreated or preincubated for 30 min with
1 µM gliotoxin and/or 20 µM proteasome
inhibitor Z–LLL–H (MG132), and stimulated
with TNF for 20 min, where indicated.
Cytoplasmic extracts were prepared by
immediate lysis in the presence of 10 mM of
iodoacetamide, blotted and immunodetected
with a polyclonal anti-IκBα antibody directed
against the carboxyl terminus. (d) Lack of
gliotoxin-mediated inhibition of ubiquitin-
transfer reactions in an E1/E2 in vitro system.
Yeast E1 and CDC34 enzymes were
incubated with radiolabeled GST–ubiquitin
fusion proteins in a buffer containing MgCl2
and ATP. Reactions were incubated at 37°C
for 30 min, fractionated using SDS–PAGE,
and analysed by autoradiography. m,
molecular weight markers. (e) Detection of
S32/36-phosphorylated IκBα specifically co-
precipitated with over-expressed, myc-tagged
βTrCP proteins. Cells of the 293 human
embryo kidney cell line were transfected with
a pcDNA3.1-βTrCP-myc construct [27] and,
24 h after transfection, pretreated with 1 µM
gliotoxin for 30 min and stimulated with TNF
for 20 min (+) or left unstimulated (–). Extracts
were subjected to immunoprecipitation using
coupled anti-myc-protein G-sepharose
conjugates, blotted, and immunodetected
using anti-phospho-IκBα antibody.
βTrCP∆WD(1–4) and βTrCP∆WD1 are
βTrCP deletion mutants incapable of
associating with phospho-IκBα (M.K.,
unpublished observations) and show the
background signal not resulting from
specific binding.
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Materials and methods section). Degradation of the fluoro-
genic peptide Suc–LLVY–amc was considerably inhibited
at both concentrations of gliotoxin (Table 1) with an in vitro
IC50 value of approximately 10 µM (Figure 3a), whereas
the other catalytic activities of the proteasome were inhib-
ited to a lesser extent (Table 1). Moreover, after treatment
with 1 µM of gliotoxin, a 63% inhibition of LLVY–amc-
hydrolyzing activity could be observed in crude cell
extracts of peripheral blood lymphocytes. In addition, we
isolated proteasomes from gliotoxin-treated and gliotoxin-
untreated cells from two different cell lines (see the Mate-
rials and methods section). Isolated proteasomes were
tested for their ability to hydrolyze suc–LLVY–amc and
LLE–na. A 61% inhibition of LLVY-hydrolyzing activity
was observed in HEK-293 proteasomes and a 66% inhibi-
tion of this activity was observed in BHK-21 proteasomes
when cells had been treated with 1 µM gliotoxin. In vitro
addition of 50 µM Z–LLL–H to extracts from gliotoxin-
untreated cells produced a 96% inhibition in LLVY-
hydrolyzing activity and a similar inhibition of LLE-
hydrolyzing activity, indicating that the isolated proteases
were almost 100% proteasomes.
To verify whether gliotoxin inhibits proteolytic activities
closely related to the proteasome, we tested its effect on
the activity of the proteases trypsin, chymotrypsin and
calpain at two different concentrations, 10 µM and
100 µM. Gliotoxin down-regulated the chymotrypsin-
mediated proteolysis of Suc–LLVY–amc by about 12% at
100 µM concentration. No effect was observed for trypsin.
We found ~20% inhibition of calpain proteolytic activity at
a gliotoxin concentration of 100 µM. At 10 µM gliotoxin,
the inhibition observed for all three proteases was less
than 5%. In conclusion, at concentrations used for rather
efficient proteasome inactivation, gliotoxin does not sig-
nificantly inhibit trypsin, chymotrypsin or calpain. Thus
the inhibition affects proteasomes but not proteases
related to the proteolytic activities of the proteasome. 
692 Chemistry & Biology 1999, Vol 6 No 10
Figure 2
Gliotoxin elicits the accumulation of
proteasome substrates in cell culture.
Peripheral blood mononuclear cells were
exposed to 10 µM gliotoxin or 20 µM
Z–LLL–H where indicated, or left untreated.
After 4 h of exposure to gliotoxin, gliotoxin +
1 mM DTT or Z–LLL–H, cells were lysed, and
(a) β-catenin or p53 proteasome substrates
were immunodetected using specific
antibodies. (b) Dihydrofolate reductase
(DHFR) assays were carried out as described
in the Materials and methods section.
(c) Accumulation of ornithine decarboxylase in
gliotoxin-exposed, as compared with
untreated, cells was performed by
immunological detection of the protein. 
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Table 1
Effect of gliotoxin on the different proteolytic activities of
purified proteasomes.
Inhibition (%)
Fluorogenic 100 µM 40 µM 
Catalytic activity peptide gliotoxin gliotoxin
Chymotrypsin-like LLVY–amc 95 72
Trypsin-like LSTR–amc 37 39
Peptidylglutamyl LLE–na 34 6
hydrolase
Proteolytic activities were measured with fluorogenic peptides as
described in the Materials and methods section. 5 µg of 20S
proteasome were incubated for 20 min at 37°C with gliotoxin at final
concentrations of 40 µM or 100 µM and one of the listed fluorogenic
peptides at the indicated concentrations. Activities are expressed
relative to no gliotoxin treatment (control), equal to 0% inhibition.
Indicated values are means of three experiments.
Gliotoxin acts as a noncompetitive inhibitor of the 20S
proteasome
Gliotoxin inhibited proteolysis of Suc–LLVY–amc, as
shown by the characteristic pattern of the Lineweaver–
Burk plots (Figure 3b). Measurements were taken with a
no-gliotoxin control and two different concentrations of
gliotoxin (10 and 60 µM), and linear regression analysis
was performed on the experimental data. The diminution
of the Vmax of the proteasomal chymotrypsin-like activity
with increasing drug concentration, together with the con-
stant Km, demonstrate that gliotoxin is a noncompetitive
inhibitor for the degradation of Suc–LLVY–amc by the
20S proteasome.
As the disulfide bridge of gliotoxin has been shown to be
essential for the majority of its physiological effects, we
decided to examine whether it was also involved in pro-
teasome inhibition. Incubation of purified 20S protea-
somes with DTT suppresses the effect of gliotoxin on the
degradation of Suc–LLVY–amc in a dose-dependent
manner. In the absence of DTT, 40 µM gliotoxin inhib-
ited degradation of this peptide by nearly 70%. DTT
(5 mM) reduced the effect of gliotoxin to less than half,
and 10 mM DTT completely abolished its inhibition of
proteasome activity (Figure 4a). When gliotoxin was
preincubated with the 20S proteasome, addition of 10 mM
DTT could fully restore proteasome Suc–LLVY-
hydrolyzing activity (Figure 4b), indicating that inhibition
of the 20S proteasome by gliotoxin is a reversible phenom-
enon. The chemical dissociation of the disulfide bridge
was achieved by preincubating gliotoxin with DTT
because low molecular weight thiols are able to reduce
gliotoxin to the dithiol compound. The latter compound
but not the bis(methyl)thio form may be re-oxidized to
gliotoxin (Figure 4c) [3]. On the contrary, glutathione
(reduced form GSH), used at the same concentration as
DTT, was unable to abolish the gliotoxin effect on protea-
somes (Figure 4a). Consistent with the reversibility of
gliotoxin-mediated proteasome inhibition observed in our
experiments, incubation of gliotoxin-treated HeLa cells
with 1 mM of DTT in the culture medium partially
restores TNF-induced NF-κB binding to its consensus
sequence (Figure 4d). Furthermore, to test whether intra-
cellular glutathione levels, which are in the range of
1–10 mM [41], interfere with the inhibitory capacity of
gliotoxin, we performed a dose–response experiment for
1, 5 and 10 mM glutathione or DTT in comparison
(Figure 4e). Reduced glutathione is not able to reverse the
inhibitory effect of gliotoxin on IkBα proteolysis, which is
in contrast to DTT. We conclude that the inhibitory
effect of gliotoxin on the proteasome depends on an intact
disulfide bridge of the molecule.
Gliotoxin has drawn considerable attention because of its
involvement in fungal diseases, especially in immunocom-
promised patients. Prior attempts to study its molecular
mechanism of action hinted at the importance of the mol-
ecule’s disulfide bridge but failed to yield a satisfactory
explanation for such diverse effects as suppression of
antigen processing, induction of apoptosis and suppression
of NF-κB activation in stimulated cells. Our results
demonstrate that gliotoxin is an inhibitor of 20S protea-
somes and, as such, inhibits the degradation of
Suc–LLVY–amc, which is a target for the proteasomal
chymotrypsin-like activity. The drug acts as a noncompet-
itive proteasome inhibitor, as shown by the characteristic
pattern of the Lineweaver–Burk plot. Gliotoxin may
target the proteasome by reversible covalent modification
involving mixed disulfide bonds at or near the active site
of the chymotrypsin-like activity. The slight inhibition of
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Figure 3
Gliotoxin inhibits the proteasome in vitro. (a) Quantitative effect of
gliotoxin on the hydrolysis of Suc–LLVY–amc by the 20S proteasome.
Biochemically purified 20S proteasome (5 µg) was incubated for
20 min at 37°C with the indicated concentrations gliotoxin and 80 µM
of Suc–LLVY–amc. Proteasome activity was measured as described in
the Materials and methods section. (b) Lineweaver–Burk analysis of
gliotoxin-mediated inhibition of Suc–LLVY–amc hydrolysis. 20S
proteasome (5 µg) was incubated at 37°C with different
concentrations of Suc–LLVY–amc. l, in the absence of gliotoxin; n, in
the presence of 10 µM or, s, 60 µM of gliotoxin. Activities were
measured as described in the Materials and methods section, and
linear regression analysis was applied to experimental data.
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the degradation of the other peptides (Table 1) could also
be due to steric hindrance by gliotoxin, which may
obstruct substrate access to the catalytic sites. We tested
the effect of gliotoxin on chymotrypsin, trypsin, and
calpain, and observed no significant inhibitory effect. 
Interestingly, the target of gliotoxin, namely the chymo-
trypsin-like activity of the proteasome, can also be inhib-
ited by amyloid B protein [42] or the antitumor drug
aclacinomycin A [43]. The fungal metabolite cyclo-
sporine A, which has immunosuppressive effects, has also
694 Chemistry & Biology 1999, Vol 6 No 10
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Gliotoxin-mediated proteasome and NF-κB inhibition depend on an
intact bicyclic structure featuring the disulfide bridge. (a) Gliotoxin-
mediated inhibition of the proteasome chymotrypsin-like activity after
preincubation of gliotoxin with or without DTT or glutathione at 5 mM
or 10 mM concentration. Pretreated gliotoxin was incubated with 5 µg
20S proteasome to give a final concentration of 40 µM. The
degradation of Suc–LLVY–amc was measured as described in the
Materials and methods section. Activities are expressed relative to no
gliotoxin treatment (control) that equals 100% activity. (b) Reversal of
gliotoxin-mediated proteasome inhibition by DTT. Proteasome (5 µg)
was preincubated with and without gliotoxin at 40 µM. DTT (5 mM)
was added to the preincubation mixture, and the degradation of
Suc–LLVY–amc was measured as described in the Materials and
methods section. Activities are expressed relative to no gliotoxin
treatment (control). (c) Chemical structures of gliotoxin and its dithiol
and bisdethiobis(methylthio) modifications. (d) Reversibility of gliotoxin-
mediated suppression of NF-κB activation. HeLa cells were incubated
with or without 1 mM DTT before TNF stimulation, and gliotoxin was
added to 1 µM final concentration where indicated. Electrophoretic
mobility shift analysis was carried out as described in Figure 1a.
(e) Gliotoxin at 1 µM concentration was preincubated for 10 min at
37°C with or without 1 mM DTT or glutathione (reduced form).
Preincubation mixtures were added to HeLa cells. After 30 min, cells
were stimulated with TNF for 20 min where indicated and immediately
lysed. Equal amounts of extracts were fractionated by SDS–PAGE,
blotted and immunodetected with a polyclonal anti-IκBα antibody.
been shown to inhibit this activity and therefore prevent
NF-κB activation [44]. Gazos Lopes et al. [45] induced
apoptosis in Rat-1 and PC12 cells using inhibitors of the
chymotrypsin-like activity. This phenomenon was also
observed in L1210 leukemia cells [46]. We observed that
gliotoxin inhibits NF-κB activation in interleukin-2-pre-
treated peripheral blood mononuclear cells (data not
shown), as other authors have observed in T and B cells
[11], and strongly induces apoptosis in many cell types
([6,47–49], and our own observations). Induction of apop-
tosis mediated by gliotoxin is preceded by phosphoryla-
tion of histone H3 [50], but the actual trigger remains
unknown. We propose that gliotoxin-mediated inhibition
of the proteasomal chymotrypsin-like activity accounts for
the drug’s pro-apoptotic effect. The latter is in keeping
with the drug’s suppression of NF-κB activation because
NF-κB is known to control the expression of anti-apop-
totic proteins [51–53] such as c-IAP1 and c-IAP2 [54,55] or
IEX-1L [56]. This gliotoxin-mediated inhibition of the
anti-apoptotic program is accompanied by an accumula-
tion of intact p53 (Figure 2a), which favors apoptosis [45].
Furthermore, proteasome mutants in yeast lacking the
chymotrypsin-like activity accumulate ubiquitinated pro-
teins when subjected to heat stress or when grown in the
presence of canavanine [57,58]. We observe the accumula-
tion of ubiquitinated IκBα when cells are stimulated with
TNF in the presence of gliotoxin (Figure 1c). The chy-
motrypsin-like activity plays a crucial role in substrate
degradation by proteasomes and was specifically associ-
ated with IκBα degradation [59].
The efficiency of gliotoxin is noteworthy because concen-
trations as low as 100 nM can affect NF-κB activation in cell
cultures [11]. Gliotoxin at 1 µM (Figure 1) can largely
prevent NF-κB activation, whereas a concentration of about
20 µM of the inhibitor Z–LLL–H [60] is necessary to reli-
ably produce the same effect [61]. Our results indicate that
the disulfide bridge in the bicyclic molecular structure of
gliotoxin is necessary for inhibition of proteasome activity,
because addition of DTT to gliotoxin-pretreated protea-
somes prevented Suc–LLVY–amc proteolysis. However,
the dethio compound bisdethiobis(methylthio)gliotoxin
(Figure 4c) acts as a platelet-activating-factor antagonist [8],
indicating that not all physiological properties of the drug
depend on an intact disulfide bridge.
Because of its general toxicity, gliotoxin can only have
limited application as a drug. It was extensively studied as
an immunosuppressor used in transplantation, with inter-
mediate success [62]. The relatively selective targeting of
one particular proteolytic activity of the proteasome,
however, may incite further research into the characteris-
tics of this molecule and its interaction with proteasomes. 
The secondary fungal metabolite gliotoxin has a multi-
tude of effects, with proteasome inhibition causing many
of them. The immunosuppressive property of gliotoxin,
which should rely mainly on its inhibition of a specific pro-
teolytic activity of proteasomes, focuses attention on the
role of proteasomes as possible targets in several important
fungal diseases. Further investigation of the molecular
mechanisms of mycotoxin action on proteasome activity
should be useful for the development of new drugs in the
management of fungal disease.
Significance
The fungal secondary metabolite gliotoxin causes many
toxic effects, decimates cattle exposed to this agent, and
is life-threatening for immunocompromised patients suf-
fering from disseminated aspergillosis. Gliotoxin induces
apoptosis in a number of cell types and suppresses acti-
vation of the anti-apoptotic transcription factor NF-κB.
We describe the mechanism for many of these effects
elicited by gliotoxin, which primarily targets the protea-
somal chymotrypsin-like proteolytic activity. Gliotoxin is
a highly efficient proteasome inhibitor in vivo and in
vitro. It acts in a noncompetitive way, as shown by
Lineweaver–Burk analysis. The disulfide bridge in the
heterobicyclic structure of gliotoxin is crucial for the
inhibition of the catalytic activity of the proteasome,
because destruction of this bridge by the strong reducing
agent dithiothreitol reverses the inhibitory effect of the
drug, whereas intracellular glutathione concentrations
cannot neutralize it. 
Although the success of gliotoxin as an immunosuppres-
sive agent in transplantation was limited, gliotoxin may
serve as a highly efficient inhibitor of specific proteolytic
activities in studies of proteasome-mediated degradation
in vitro or in cell culture. Further investigation into the
precise way gliotoxin exerts its toxic effect on host cell
proteasomes may provide useful in developing pharma-
ceutical agents for the management of aspergillosis.
Secondary metabolites of invasive fungi may very often
be considered potential candidates for targeting host cell
proteasome catalytic activities, largely accounting for
their pathogenicity.
Materials and methods
Reagents and chemicals 
Suc–LLVY–amc, N-t-Boc-Leu-Ser-Thr-Arg-7-amido-4-methylcoumarin
(LSTR–amc), N-Cbz-Leu-Leu-Glu-β-naphthylamine (LLE–na), 7-amido-
4-methylcoumarin (amc), β-naphthylamine (na), rabbit muscle calpain,
bovine pancreas α-chymotrypsin, trypsin, β-nicotineamidedihydrogen-
phosphate (NADPH), dihydrofolate, iodoacetamide, human thrombine,
and Gliocladium fimbriatum gliotoxin were purchased from Sigma
Chemical Company. Recombinant interleukin-2 was from EuroCetus,
Netherlands. The short peptide proteasome inhibitor Z–LLL–H
(MG132) was synthesized as previously described [60]. Human
recombinant TNF was provided by the MRC ADP reagent program.
[γ-32P]ATP was purchased from Amersham. Lipofectamine PLUS trans-
fection reagent was from Life Sciences (France). Anti-human IκBα
(MAD3) monoclonal antibody 10B [63], polyclonal anti-IκBα antibody
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directed against the carboxyl terminus (Santa Cruz), anti-p53 (Santa
Cruz), anti-SP1 (Santa Cruz), anti-β-catenin (Transduction Laborato-
ries), and anti-ornithine decarboxylase (Valbiotech) antibodies were
used for immunodetection. DHFR activity was measured as described
in [64], using dihydrofolate and reduced β-NADPH as (co)substrates.
Cell culture
HeLa cells and cells of the 293 human embryo kidney cell line were
cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum. BHK-21 cells were cultured in BHK-medium from
Gibco, supplemented with tryptose broth and 5% fetal calf serum.
Ficoll-purified human peripheral blood mononuclear cells were cultured
in RPMI 1640 medium containing 10% fetal calf serum. The latter cells
were prestimulated with 20 ng/ml recombinant interleukin-2 for 5 days.
Transfections were carried out using Lipofectamine PLUS according to
manufacturer’s instructions (LifeSciences).
Preparation of cytoplasmic and nuclear extracts by fractionation
Cells were harvested by trypsin treatment, washed with prewarmed
phosphate-buffered saline (PBS), and centrifuged. Sedimented cells
were gently resuspended and disrupted in 2 ml of lysis buffer containing
0.2% Triton X-100 and protease inhibitors. Where indicated, phos-
phatase inhibitors and iodoacetamide were added to inhibit phos-
phatases and isopeptidases. After collecting 0.2 ml to prepare
cytoplasmic extracts, 50 ml of lysis buffer was added to the remaining
sample which was then centrifuged to sediment nuclei. After careful
removal of the supernatant, nuclear pellets were resuspended and main-
tained with permanent agitation for 1 h at 4°C in 50 µl of a hyper-
osmotic buffer containing protease inhibitors. Soluble fractions
extracted from the nuclear suspension were recovered after centrifuga-
tion at 15,000 g for 15 min. Lysis buffer was 50 mM NaCl, 10 mM
HEPES pH 8.0, 500 mM sucrose, 1 mM EDTA, 0.5 mM spermidine,
0.15 mM spermine and 0.2% Triton X-100. Hypertonic buffer was
350 mM NaCl, 10 mM HEPES pH 8.0, 25% glycerol, 0.1 mM EDTA,
0.5 mM spermidine and 0.15 mM spermine. Protease inhibitors — 1 mM
phenylmethylsulfonyl fluoride, 10 µM leupeptin, 1 µM pepstatin and
50 µM L-1-chloro-3-(4-tosylamido)-4-phenyl-2-butanone—were included
in lysis buffers. Absence of nucleoplasmatic contamination from cyto-
plasmic extracts was checked by detection of SP1 transcription factor.
Electrophoretic mobility shift assays
NF-κB DNA binding assays were performed as described previously
[36], and contained 4 µg of nuclear extract incubated for 15 min at room
temperature with a [γ-32P]ATP-labeled double-stranded oligonucleotide
carrying the κB motif found in the HIV-1 enhancer (5′-ACAAGGGA-
CTTTCCGCTGGGACTTTCCAGGGA-3′). Free DNA was resolved
from DNA–protein complexes on a nondenaturing 6% polyacrylamide
gel, and positions of radioactive species were determined by autoradi-
ography of the dried gel. Competition experiments were performed by
adding a 40-fold molar excess of homologous, unlabeled oligonu-
cleotide to each sample prior to addition of the radiolabeled probe.
Western blot analysis
Aliquots of degradation reactions or cytoplasmic extracts were sepa-
rated on 10–12% SDS–PAGE gels and transferred onto nitrocellulose
membranes (Sartorius) by semi-dry electroblotting. Immobilized antigen-
antibody complexes were detected with horseradish peroxidase-conju-
gated donkey anti-mouse or anti-rabbit immunoglobulins and an
enhanced chemiluminescence detection system (ECL, Amersham).
Confocal microscopy
HeLa Cells were grown on microscope slide cover slips, washed
twice in ice-cold PBS, fixed with paraformaldehyde and Triton X-100,
and subsequently washed three times in PBS. Fixed cells were incu-
bated for 1 h with 2 µg/ml primary antibody (polyclonal anti-ODC anti-
body from Valbiotech) in PBS/10% FCS/0.1% Tween-20. After five
washes in PBS/10% FCS/0.1% Tween-20, cells were incubated with
the secondary antibody, an FITC-coupled donkey anti-rabbit antibody.
After repetition of the washing procedure, a drop of Vectashield
mounting medium was applied to protect the coupled FITC moieties
from photobleaching effects. Confocal microscopy was performed on
a Leica TCS4d using Leica Scanware to process images. To compare
fluorescence intensities of cells exposed to gliotoxin or left untreated,
the same settings of the photomultiplier were used. Quantification was
carried out using image analysis utilities (Leica).
Immunoprecipitations
For immunoprecipitation experiments, 200 µg of cytoplasmic extract
were incubated with anti-myc-agarose conjugates (Santa Cruz) for
60 min at 4°C. Precipitated beads were washed ten times in PBS con-
taining 1% NP-40 and both protease and phosphatase inhibitors. Anti-
body-antigen complexes were disrupted by boiling in gel loading buffer
(Pierce). Precipitated proteins were fractionated by SDS–PAGE and
electroblotted onto nitrocellulose membranes.
Purification of proteins
20S proteasome purification to homogeneity. Human placenta
was cut into small pieces at 4°C and homogenized in 20 mM Hepes,
pH 7.8, 0.1 mM EDTA, 1 mM 2-mercaptoethanol pH 7.8 (4 ml/1 g of
tissue) using a Elvehjem potter homogenizer with a Teflon piston. The
homogenate was centrifuged at 25,000 g for 2 h at 4°C. The protea-
some was purified as previously described [65]. Briefly, the placenta
homogenate supernatant was subjected to ammonium sulfate precipi-
tations (35 and 60% saturation). The pellet of the second precipitation
was resuspended in 10 mM Tris–HCl pH 7.2, 100 mM KCl, 0.1 mM
EDTA, 1 mM 2-mercaptoethanol, and dialysed at 4°C against the same
buffer. The first ion-exchange chromatography was performed on a
TosoHaas DEAE-5PW column, with a Beckman Gold liquid chromato-
graph. Purification was achieved in three additional chromatographic
steps: ion-exchange on a Mono-Q HR 5/5 column (Pharmacia), gel fil-
tration on a Superose 6 column (Pharmacia), and hydroxyapatite on a
HA-1000 column (TosoHaas). Purified proteasome was dialysed
against a buffer of 0.1 M Hepes pH 7.8.
Proteasome preparation by ultracentrifugation. Cells were lysed
in lysis buffer containing 0.2% Triton X-100. Cell debris was eliminated
by centrifugation at 5,000 g for 5 min at 4°C. The supernatant was sub-
jected to ultracentrifugation at 100,000 g for 16 h at 4°C. The pellet
was resuspended in 25 mM Tris buffer, pH 7.5.
Protein and peptidase activity assays
Protein concentrations were determined by the bicinchoninic acid
assay (Pierce). Assays of 20S proteasome peptidase activities were
carried out with fluorogenic peptides. Suc–LLVY–amc was used for
chymotrypsin-like activity, LSTR-amc for trypsin-like activity, and
LLE–na for peptidylglutamyl-peptide hydrolase activity. The incubation
mixture contained 5 µg 20S proteasome, 0.1 M Hepes pH 7.8 with the
appropriate peptide substrate concentration in a final volume of 200 µl.
Incubation was at 37°C for 20 min, and the reaction was stopped with
300 µl of acid or ethanol depending on the peptide used. After addition
of 2 ml distilled water, fluorescence was monitored on a Perkin Elmer
LS-5B spectrofluorimeter. The excitation/emission wavelengths were
350 nm/440 nm and 333 nm/410 nm for aminomethylcoumarin and
β-naphthylamine reagents, respectively. Calpain activity was measured
using succinylated casein according to the QuantiCleave Protease
Assay Kit II (Pierce). For inhibitory assays, the gliotoxin stock solution
was prepared in dimethyl sulfoxide. Gliotoxin at different concentrations
was preincubated with 5 µg of the indicated peptide-amc molecules for
15 min at room temperature in 0.1 M Hepes pH 7.8. The respective
substrates were added to give a final volume of 200 µl, and activities
were measured using fluorogenic peptides as described above.
In vitro ubiquitin transfer reactions
Recombinant yeast E1 (0.1 µg) and CDC34 (2 µg) were incubated with
32P-radiolabeled GST–ubiquitin (3500 cpm per 20 µl reaction volume)
expressed from pGex2TK vector (Pharmacia) in 20 mM Tris pH 7.5,
2 mM ATP, and 10 mM MgCl2. Reaction mixtures were incubated at
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37°C for 30 min and fractionated using SDS–PAGE. Gels were dried
and analysed by autoradiography.
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